Farxiga (dapagliflozin) NDC 70518-4614

Product information

Brand name (proprietary)

Farxiga

Generic name (nonproprietary)

dapagliflozin

Active ingredients

Dapagliflozin propanediol — 5 mg/1

Dosage form

Tablet, Film coated

Route

Oral

Labeler

REMEDYREPACK INC.

Product type

Prescription drug

Marketing category

NDA — New Drug ApplicationApplication NDA 202293

Marketing start

Apr 23, 2026

Listing expires

Dec 31, 2027

Other FDA classes

Sodium-Glucose Transporter 2 Inhibitors (Mechanism)

Identifiers

Product ID 70518-4614_5bc230f9-4eb9-3de2-e063-6394a90aa3aaSPL ID 5bc230f9-4eb9-3de2-e063-6394a90aa3aa

Pharmacologic class

Sodium-Glucose Cotransporter 2 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518461400 followed by a unit qualifier and the quantity Copy

Package 70518-4614-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

Other NDCs under NDA 202293

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.